儿童生长激素缺乏症市场 - 全球产业规模、份额、趋势、机会和预测（按类型、按产品、按应用、按药物、按配销通路、按地区和竞争细分，2020-2030 年）

2024 年全球儿童生长激素缺乏症 (PGHD) 市场价值为 38.7 亿美元，预计到 2030 年将达到 64.1 亿美元，预测期内复合年增长率为 8.77%。该市场涵盖了旨在治疗儿童生长激素缺乏症的各种诊断工具和治疗解决方案。由于基因异常、先天性问题、脑外伤和医疗副作用等因素导致的 PGHD 发生率不断上升，持续增加了对荷尔蒙疗法的需求。生物技术的进步促进了创新重组人类生长激素的发展，提高了治疗效果和患者的依从性。值得注意的是，辉瑞和OPKO的每週一次的somatrogon注射于2022年获得欧盟批准，这反映了治疗创新的重大进步。此外，人们对合成荷尔蒙疗法的认识和接受度不断提高，以及特纳氏症等疾病的盛行率不断上升，进一步促进了市场的扩张。不断增长的研发活动，加上支持性的监管环境和有针对性的治疗可用性，使 PGHD 市场在全球范围内实现持续成长。

关键市场驱动因素

儿童生长激素缺乏症（PGHD）盛行率不断上升

主要市场挑战

生长激素治疗费用高昂

主要市场趋势

生物和生物相似药生长激素疗法

目录

第 1 章：产品概述

第二章：研究方法

第三章：执行摘要

第四章：顾客之声

第五章：全球儿童生长激素缺乏症市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依类型（先天性生长激素缺乏症、后天性生长激素缺乏症、特发性生长激素缺乏症）
  • 副产品（粉末、溶剂）
  • 依应用（生长激素缺乏症、特发性身材矮小症、特纳氏症、小于胎龄儿、普拉德-威利症候群、其他）
  • 按药物（Genotropin、Humatrope、Norditropin Flexpro、其他）
  • 按配销通路（医院药房、零售药房、网路药房、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第六章：北美儿童生长激素缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲儿童生长激素缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 英国
  • 义大利
  • 法国
  • 西班牙

第八章：亚太地区儿童生长激素缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：南美儿童生长激素缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 巴西
  • 阿根廷
  • 哥伦比亚

第十章：中东和非洲儿童生长激素缺乏症市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 最新动态
• 产品发布
• 併购

第 13 章：全球儿童生长激素缺乏症市场：SWOT 分析

第 14 章：竞争格局

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring BV
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen Pharma

第 15 章：策略建议

第16章调查会社について・免责事项

The Global Pediatric Growth Hormone Deficiency (PGHD) Market was valued at USD 3.87 billion in 2024 and is projected to reach USD 6.41 billion by 2030, growing at a CAGR of 8.77% during the forecast period. This market encompasses a wide range of diagnostic tools and therapeutic solutions aimed at managing growth hormone deficiency in children. The rising incidence of PGHD, caused by factors such as genetic abnormalities, congenital issues, brain trauma, and side effects of medical treatments, continues to increase demand for hormone-based therapies. Advancements in biotechnology have led to the development of innovative recombinant human growth hormones, improving both treatment efficacy and patient compliance. Notably, Pfizer and OPKO's once-weekly somatrogon injection received EU approval in 2022, reflecting a significant stride in therapeutic innovation. Moreover, increasing awareness and acceptance of synthetic hormone therapy, alongside the documented prevalence of conditions like Turner Syndrome, further contribute to the market's expansion. Growing R&D activity, combined with a supportive regulatory environment and targeted treatment availability, positions the PGHD market for sustained growth globally.

Key Market Drivers

Increasing Prevalence of Pediatric Growth Hormone Deficiency (PGHD)

The rising number of pediatric growth hormone deficiency cases is a major growth driver for the global PGHD market. This increase is largely attributable to genetic predispositions, premature births, and improved diagnostic capabilities. Children born with a family history of GHD or with low birth weight are more prone to hormonal imbalances, prompting early screening and treatment. Enhanced neonatal care has also improved survival rates of premature infants, many of whom later require hormonal support for growth. Additionally, broader access to genetic testing and heightened medical surveillance has led to earlier diagnosis and a higher number of treated cases. As awareness around PGHD grows, healthcare providers and caregivers are more proactive in seeking timely intervention, contributing to rising treatment demand.

Key Market Challenges

High Cost of Growth Hormone Therapy

The significant cost associated with growth hormone therapy remains a key challenge for market growth. These treatments often involve long-term regimens with regular injections, which can accumulate substantial expenses for families. In regions with limited insurance coverage or insufficient healthcare infrastructure, the affordability of such therapies becomes a major barrier. The high treatment cost can also deter therapy initiation or result in poor adherence, ultimately impacting patient outcomes and limiting market expansion, particularly in low- and middle-income countries.

Key Market Trends

Biological and Biosimilar Growth Hormone Therapies

A notable trend shaping the PGHD market is the increased adoption of biological and biosimilar hormone therapies. Biological products, produced using living cells, offer high specificity and therapeutic precision, while biosimilars provide a cost-effective alternative with similar clinical efficacy. The growing entry of biosimilars into the market has fostered greater competition, resulting in improved affordability and access. As biosimilars become more widely accepted, healthcare providers can tailor treatment regimens with a broader portfolio of therapeutic options, making hormone replacement therapy more accessible and personalized.

Key Market Players

• Novo Nordisk A/S
• Eli Lily and Company
• Novartis AG
• Merck KgaA
• Pfizer Inc.
• Ferring B.V
• Genentech Inc
• BioParteners GmbH
• LG Chem Ltd.
• Ipsen Pharma

Report Scope:

In this report, the Global Pediatric Growth Hormone Deficiency Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Growth Hormone Deficiency Market, By Type:

• Congenital GH Deficiency
• Acquired GH Deficiency
• Idiopathic GH Deficiency

Pediatric Growth Hormone Deficiency Market, By Product:

• Powder
• Solvent

Pediatric Growth Hormone Deficiency Market, By Application:

• Growth Hormone Deficiency
• Idiopathic Short Stature
• Turner Syndrome
• Small For Gestational Age
• Prader-Willi Syndrome
• Others

Pediatric Growth Hormone Deficiency Market, By Drug:

• Genotropin
• Humatrope
• Norditropin FlexPro
• Others

Pediatric Growth Hormone Deficiency Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Pediatric Growth Hormone Deficiency Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Growth Hormone Deficiency Market.

Available Customizations:

Global Pediatric Growth Hormone Deficiency market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Applications
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Growth Hormone Deficiency Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Congenital GH Deficiency, Acquired GH Deficiency, Idiopathic GH Deficiency)
  • 5.2.2. By Product (Powder, Solvent)
  • 5.2.3. By Application (Growth Hormone Deficiency, Idiopathic Short Stature, Turner Syndrome, Small For Gestational Age, Prader-Willi Syndrome, Others)
  • 5.2.4. By Drug (Genotropin, Humatrope, Norditropin Flexpro, Others)
  • 5.2.5. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.6. By Region
  • 5.2.7. By Company (2024)
• 5.3. Market Map

6. North America Pediatric Growth Hormone Deficiency Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Product
  • 6.2.3. By Application
  • 6.2.4. By Drug
  • 6.2.5. By Distribution Channel
  • 6.2.6. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By Drug
      • 6.3.1.2.5. By Distribution Channel
  • 6.3.2. Canada Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By Drug
      • 6.3.2.2.5. By Distribution Channel
  • 6.3.3. Mexico Pediatric Growth Hormone Deficiency Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By Drug
      • 6.3.3.2.5. By Distribution Channel

7. Europe Pediatric Growth Hormone Deficiency Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Product
  • 7.2.3. By Application
  • 7.2.4. By Drug
  • 7.2.5. By Distribution Channel
  • 7.2.6. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By Drug
      • 7.3.1.2.5. By Distribution Channel
  • 7.3.2. United Kingdom Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By Drug
      • 7.3.2.2.5. By Distribution Channel
  • 7.3.3. Italy Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecasty
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By Drug
      • 7.3.3.2.5. By Distribution Channel
  • 7.3.4. France Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By Drug
      • 7.3.4.2.5. By Distribution Channel
  • 7.3.5. Spain Pediatric Growth Hormone Deficiency Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By Drug
      • 7.3.5.2.5. By Distribution Channel

8. Asia-Pacific Pediatric Growth Hormone Deficiency Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Product
  • 8.2.3. By Application
  • 8.2.4. By Drug
  • 8.2.5. By Distribution Channel
  • 8.2.6. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By Drug
      • 8.3.1.2.5. By Distribution Channel
  • 8.3.2. India Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By Drug
      • 8.3.2.2.5. By Distribution Channel
  • 8.3.3. Japan Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By Drug
      • 8.3.3.2.5. By Distribution Channel
  • 8.3.4. South Korea Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By Drug
      • 8.3.4.2.5. By Distribution Channel
  • 8.3.5. Australia Pediatric Growth Hormone Deficiency Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By Drug
      • 8.3.5.2.5. By Distribution Channel

9. South America Pediatric Growth Hormone Deficiency Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Product
  • 9.2.3. By Application
  • 9.2.4. By Drug
  • 9.2.5. By Distribution Channel
  • 9.2.6. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By Drug
      • 9.3.1.2.5. By Distribution Channel
  • 9.3.2. Argentina Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By Drug
      • 9.3.2.2.5. By Distribution Channel
  • 9.3.3. Colombia Pediatric Growth Hormone Deficiency Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By Drug
      • 9.3.3.2.5. By Distribution Channel

10. Middle East and Africa Pediatric Growth Hormone Deficiency Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Product
  • 10.2.3. By Application
  • 10.2.4. By Drug
  • 10.2.5. By Distribution Channel
  • 10.2.6. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By Drug
      • 10.3.1.2.5. By Distribution Channel
  • 10.3.2. Saudi Arabia Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By Drug
      • 10.3.2.2.5. By Distribution Channel
  • 10.3.3. UAE Pediatric Growth Hormone Deficiency Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By Drug
      • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challanges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Pediatric Growth Hormone Deficiency Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Novo Nordisk A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Eli Lily and Company
• 14.3. Novartis AG
• 14.4. Merck KgaA
• 14.5. Pfizer Inc.
• 14.6. Ferring B.V
• 14.7. Genentech Inc
• 14.8. BioParteners GmbH
• 14.9. LG Chem Ltd.
• 14.10.Ipsen Pharma

15. Strategic Recommendations

16. About Us & Disclaimer